Anti-TNF-α therapy for orofacial granulomatosis: Proceed with caution [6]

Gut

Volumn 55, Issue 10, 2006, Pages 1524-1525

  Gaya, Daniel R ^a   Aitken, S ^a   Fennell, J ^a   Satsangi, J ^a   Shand, A G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; FLUCLOXACILLIN; INFLIXIMAB; PENICILLIN G; PIPERACILLIN; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; BLOOD CULTURE; CASE REPORT; CELLULITIS; CLINICAL FEATURE; DRUG INFUSION; ERYTHEMA; FACE EDEMA; FACE PAIN; FEMALE; FEVER; FOLLOW UP; GRANULOMATOSIS; HUMAN; LETTER; OROFACIAL GRANULOMATOSIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CELLULITIS; DRUG ERUPTIONS; EDEMA; FACIAL PAIN; FEMALE; FEVER; GRANULOMATOSIS, OROFACIAL; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749160795     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.099143     Document Type: Letter

References (5)

1. Weisenfeld D, Ferguson MM, Mitchell DN, et al. Oro-facial granulomatosis - a clinical and pathological analysis. Q J Med 1985;54:101-13.
2. Hegarty A, Hodgson T, Porter S. Thalidomide for the treatment of recalcitrant oral Crohn's diease and orofacial granulomatosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:576-85.
3. Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn's disease. Inflamm Bowel Dis 2001;7:38-42.
4. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004;10:333-8.
5. Papadakis KA, Shayne OA, Vasiliamskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005;100:75-9.